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Fibrates, including fenofibrate and bezafibrate,
are a group of hypolipidemic drugs that are com-
monly used to treat dyslipidemia which is associat-
ed with type 2 diabetes mellitus and metabolic syn-
drome (1). At a molecular level, fibrates bind to per-
oxisome proliferator-activated receptors (PPAR)
and regulate the transcription of genes for different
proteins, particularly those involved in lipid metab-
olism (2). Fenofibrate binds primarily to PPARα,
while bezafibrate is an agonist for all three PPAR
isoforms (3). In addition, fibrates exert numerous
biological activities which are PPAR-independent
(4, 5).
It has been found that fibrates regulate
enzymes belonging to the mitochondrial family of 2-
oxoacid dehydrogenases (6, 7). 2-oxoglutarate dehy-
drogenase (2-OGDH ñ EC 1.2.4.2; also known as
the α-ketoglutarate dehydrogenase, α-KGDH),
branched-chain α-ketoacid dehydrogenase
(BCKDH) and pyruvate dehydrogenase (PDH)
share some common structural and functional fea-
tures and they all catalyze the decarboxylation of
their respective 2-oxoacids (8).
2-OGDH, the key control enzyme of a tricar-
boxylic acid cycle, catalyzes the conversion of 2-
oxoglutarate (2-OG), coenzyme A and NAD+ to
succinyl-CoA, NADH and CO2. The complex con-
sists of multiple copies of three catalytic subunits: 2-
oxoglutarate dehydrogenase (E1), dihydrolipoamide
succinyltransferase (E2) and dihydrolipoamide
dehydrogenase (E3). The E1 and E2 subunits are
unique for the 2-OGDH, while E3 subunit is loose-
ly bounded to this complex and after dissociation it
can associate with other complexes belonging to the
family of 2-oxoacid dehydrogenases.
It has been shown that fibrates increase liver 2-
OGDH and BCKDH complex activities and stimu-
late 2-OG and branched-chain amino acid catabo-
lism, respectively (6, 9). This effect is especially
marked in rats fed a low-protein diet (7, 10).
Stimulation of 2-OGDH and BCKDH in protein-
restricted rats has been demonstrated not only for
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Abstract: 2-oxoglutarate dehydrogenase (2-OGDH) is the key regulatory enzyme of cell metabolism. It has
been previously demonstrated that in rats subjected to protein restriction low, clinically relevant doses of
fibrates up-regulate liver 2-OGDH and promote 2-oxoglutarate catabolism. The aim of the present study was to
evaluate the effect of low doses of fenofibrate and bezafibrate on renal 2-OGDH complex in rats fed low-pro-
tein chow. Fibrates were administered for 14 days to Wistar male rats at one daily dose of 5, 10 or 20 mg/kg
b.wt./day. The 2-OGDH activity was assayed spectrophotometrically. The mRNA levels for 2-OGDH catalyt-
ic subunits (E1 and E2) and PPARα were quantified by means of semi-quantitative reverse-transcription-PCR.
2-OGDH activity increased in response to administration of fenofibrate and bezafibrate (by 11, 24, 32% and 9,
12, 21%, respectively). The difference was statistically significant for the doses of 10 and 20 mg/kg b.wt of
fenofibrate (p < 0.001) and the highest dose of bezafibrate (p < 0.05). The stimulation of 2-OGDH was not
accompanied by changes in mRNA levels for E1 and E2. In addition, the mRNA level for PPARα did not
change. It is conceivable that fibrate-induced stimulation of 2-OGDH activity can affect renal metabolism and
contribute to changes in kidney functions.
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high, experimental but also for low, more clinically
relevant doses of fibrates. In addition, fibrates may
also change mRNA levels for catalytic subunits of
the complexes, though this effect is dependent on
the dose used (9, 10, 11, 12).
Liver parenchymal and renal tubular cells
share many of the same enzymes and metabolic
pathways. It has also been shown that fibrates can
affect kidney functions (13, 14, 15). Therefore we
wanted to examine the influence of low, clinically
relevant doses (16) of fibrates on renal 2-OGDH
complex. The present study was undertaken to
investigate the in vivo effect of fenofibrate and
bezafibrate (at doses of 5, 10 and 20 mg
kg/b.wt/day) on 2-OGDH complex in the kidney of
rats fed a low-protein diet (8% protein). In addition,
mRNA levels for 2-OGDH catalytic subunits (E1
and E2) and PPARα were measured.
EXPERIMENTAL
Reagents
All chemicals used in experiments were pur-
chased from SigmañAldrich Chemical Company
(Germany). A low-protein diet (8% protein) was
bought from MP Biomedicals (USA). NG dART RT
kit and Perpetual Opti Taq DNA polymerase were
purchased from Eurx (Poland). Primers were syn-
thesized by Blirt DNA Gdansk (Poland).
Animals and experimental treatment
Animal experiments were conducted in accor-
dance with the guidelines for animal experiments
and all procedures were approved by the First Local
Ethical Committee on Animal Testing at the
Jagiellonian University, Krakow, Poland. Male
Wistar rats (from the inbred strain) were purchased
from the breeding facility of the Jagiellonian
University Faculty of Pharmacy. They were housed
four per cage and maintained under standardized
conditions of artificial 12-hours light/dark cycle in
constant room temperature (21-23OC). All rats were
fed low-protein diet (8% protein content) ad libitum
and were allowed free access to water. Rats (n = 28)
were randomized into 7 treatment groups (n = 4
each). Group 1 (control group ñ 0 mg/kg b.wt
fibrate): rats administered with 0.3% dimethylcellu-
lose solution (agentís vehicle). Groups 2, 3 and 4:
rats treated with fenofibrate (propan-2-yl 2-[4-(4-
chlorobenzoyl)phenoxy]-2-methylpropanoate) at
the dose of 5; 10 and 20 mg/kg b.wt, respectively.
Groups 5, 6 and 7: rats treated with bezafibrate (2-
(4-{2-[(4-chlorophenyl)formamido]ethyl}phe-
noxy)-2-methylpropanoic acid) at the dose of 5; 10
and 20 mg/kg b.wt, respectively. The doses were
chosen based on our earlier study on the effect of
fibrates on liver 2-OGDH complex (10). Fibrates
were administered by intragastric gavage for 14
days (once daily). On day 15, rats were sacrificed,
kidneys were excised and immediately freeze-
clamped with aluminum tongs precooled in liquid
nitrogen and then stored at -80OC until analysis.
Determination of 2-OGDH activity
Tissue extracts for the assay of renal 2-OGDH
activity were prepared as described previously (17).
Briefly, a portion of frozen renal tissue was pow-
dered in liquid nitrogen, weighed and homogenized
in an extraction buffer. 2-OGDH was then concen-
trated from the whole tissue extract by precipitation
with 9% polyethylene glycol. 2-OGDH activity (in
the presence of thiamine diphosphate in the assay
cocktail) was determined spectrophotometrically at
30OC by measuring the rate of NADH generation
from NAD+ (at 340 nm) using the saturating con-
centration of 2-OG, a substrate for 2-OGDH com-
plex (Cary 100 spectrophotometer-Varian). In con-
trast to Blair et al. (17), the assay buffer was made
without dihydrolipoamide dehydrogenase (18). One
unit of 2-OGDH complex activity is defined as the
Table 1. Sequences, concentrations and annealing temperatures of primers used in PCR.
Gene amplified Primer Primer concentration Annealing 
(product bp) Sequence (pmol/ L) temperature (OC)
E1 5'- GGA GAC AGG TAT TTG TGG AAG GC -3' 4
(347) 5'- CCA GGG AGC TTC GAC TCA GG -3' 4
65
E2 5'- AGA TGT CAG GTG GGA GAA AG -3' 4
(339) 5'- GGT TTG CTA GAA GGA GGT TG -3' 4
60
PPARα 5'- TCA GAG GTC CCT GAA CAG TG -3' 2
(510) 5'- AAG CCA TCT TCA CGA TGC TG -3' 2
60
β -actin 5'- AGC CAT GTA CGT AGC CAT CC -3' 4
(228) 5'- CTC TCA GCT GTG GTG GTG AA -3' 4
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amount of enzyme that catalyzed the formation of 1
µmol of NADH/min.
Determination of mRNA levels
Relative levels of specific mRNA for 2-OGDH
catalytic subunits (E1 and E2) and PPARα were
assessed by semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR). Total RNA
was isolated with TRI reagent (Sigma-Aldrich,
Germany) and cDNA was subsequently synthesized
using 1µg total RNA, reverse-transcriptase and oligo
dT primers (NG dART RT kit, Eurx, Poland). cDNA
was amplified with Perpetual Opti Taq DNA poly-
merase (Eurx, Poland) following the manufacturerís
instructions. PCR reactions were performed with rat-
specific primers (Table 1) that were designed for the
genes of interest using Primer-BLAST software
(NCBI). Each gene was amplified together with a
housekeeping gene β-actin (internal control). After an
initial denaturation at 95OC, PCR was carried out for
35 cycles. Each cycle consisted of denaturation at
95OC for 40 seconds, primer annealing for 30 seconds
and primer extension at 72OC for 30 seconds. The
PCR products were subjected to agarose gel elec-
trophoresis (1.5% agarose gel), stained with ethidium
bromide and analyzed by densitometry using the
Quantity One software (Bio-Rad). Obtained data
were first normalized to β-actin (in the same sample)
and then expressed relative to the control group (vehi-
cle-treated rats). The relative level of particular
mRNA in each fibrate treated group was presented
using arbitrary units (% of the control group).
Statistical analysis
Statistical calculations and graphs were done
using GraphPad Prism version 5.0 (GraphPad
Software, Inc., San Diego, CA, USA). Data were
presented as mean ±SD. Differences between
groups were determined with one-way analysis of
variance (ANOVA), followed, when appropriate, by
Bonferroni post hoc test, with acceptable signifi-
cance levels set at p < 0.05.
RESULTS
Effect of fibrates on 2-OGDH activity
Both fenofibrate and bezafibrate administered
to protein-restricted rats stimulated renal 2-OGDH
activity in a dose-dependent manner. In rats that
received 5, 10 and 20 mg/kg b.wt fenofibrate 2-
OGDH activity increased by 11%, 24% and 32% in
comparison to the control group, respectively. The
difference was statistically significant for the doses
of 10 and 20 mg/kg b.wt (p < 0.001) (Fig. 1).
Figure 1. Effect of increasing doses of fenofibrate on renal 2-OGDH activity. Rats were fed a low-protein diet and administered with 5, 10
or 20 mg/kg b.wt/day of fenofibrate or given only the vehicle (control group ñ 0 g/kg b.wt/day fenofibrate). 2-OGDH activity was deter-
mined spectrophotometrically at 30OC by measuring the rate of NADH generation at 340 nm. Data are presented as mean ± SD (n = 4). *p
< 0.001 compared to the control group.
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In bezafibrate-treated rats mean 2-OGDH
activity was 9%, 12% and 21% higher than in the
untreated animals. The difference was statistically
significant for rats given the highest dose of bezafi-
brate (p < 0.05) (Fig. 2).
Effect of fibrates on mRNA levels for E1 and E2
subunits of 2-OGDH complex
The effect of fenofibrate and bezafibrate on
mRNA levels of E1 and E2 subunits is presented in
Figure 3 and Figure 4. Mean E1 mRNA levels in rats
given 5, 10 and 20 mg/kg b.wt fenofibrate were
lower than in the control group (95 ± 1%; 95 ± 4%
and 95 ± 3% vs 100 ± 2%, respectively) (Fig. 3a).
Similarly, E2 mRNA levels decreased by 3%, 1%
and 4%, respectively as compared to vehicle-treated
animals (Fig. 3b). The differences were not statisti-
cally significant (p > 0.05).
In rats given 5, 10 and 20 mg/kg b.wt bezafi-
brate E1 mRNA levels were 1%, 6% and 6% lower
than in the control group (Fig. 4a). In rats treated
with 5 mg/kg b.wt bezafibrate E2 mRNA level was
lower, while with 20 mg/kg b.wt higher than in the
control group (91 ± 8% and 103 ± 5% vs 100 ± 2%,
respectively). Mean E2 mRNA level in rats given 10
mg/kg b.wt bezafibrate was the same as in the vehi-
cle-treated group (100 ± 6% vs 100 ± 2%) (Fig. 4b).
The differences were not statistically significant (p >
0.05).
Effect of fibrates on mRNA levels for PPARα
There was no significant difference in the
mean renal mRNA abundance for PPARα between
fenofibrate treated groups and control rats (94 ± 3%,
90 ± 3% and 93 ± 4% vs. 100 ± 11 for the control
group) (Fig. 5a). Mean relative mRNA levels for
PPARα were 4%, 5% and 7% lower in bezafibrate
treated groups than in the vehicle-treated animals (p
> 0.05) (Fig. 5b).
DISCUSSION AND CONCLUSION
This study demonstrated that administration of
low doses bezafibrate and fenofibrate to protein-
malnourished rats caused dose-dependent stimula-
tion of renal 2-OGDH activity. Taking into account
the results of the present and previous studies (10) it
can be concluded that low doses of fenofibrate and
bezafibrate increase 2-OGDH activity both in liver
and kidney of rats fed a low-protein diet.
It is well documented that 2-OGDH activity is
controlled mainly post-translationally by different
Figure 2. Effect of increasing doses of bezafibrate on renal 2-OGDH activity. Rats were fed a low-protein diet and administered with 5, 10
or 20 mg/kg b.wt/day of bezafibrate or given only the vehicle (control group ñ 0 g/kg b.wt/day bezafibrate). 2-OGDH activity was deter-
mined spectrophotometrically at 30OC by measuring the rate of NADH generation at 340 nm. Data are presented as mean ± SD (n = 4). *p
< 0.05 compared to the control group.
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factors (19). The 2-OGDH complex undergoes
allosteric inhibition by high succinyl-CoA/CoA,
NADH/NAD+ and ATP/ADP ratios (19, 20). In
addition, calcium ions increase 2-OGDH activity
(21, 22). In the present study, it was found that
fenofibrate and bezafibrate had no effect on mRNA
levels for E1 and E2 catalytic subunits. We can
speculate that fibrates exert some effects on the fac-
tors regulating 2-OGDH activity. Jiao et al. (23)
demonstrated that fenofibrate treatment increased
cellular calcium levels. In addition, clofibrate, the
parent compound of fibrates group, increases the
concentration of free CoA and reduces succinyl-
CoA level leading to the reduction of succinyl-
CoA/CoA ratio (24). It seems likely that clofibrate
analogs, fenofibrate, and bezafibrate, have a similar
effect on succinyl-CoA/CoA ratio.
Stimulation of liver BCKDH complex by
fibrates was associated with increased dephosphory-
lation of the complex (12, 25). Until recently it has
been thought that in contrast to BCKDH, the activi-
ty of 2-OGDH is not regulated by reversible phos-
phorylation. However, recent study demonstrated
that phosphorylation of 2-OGDH mediated by c-jun
N-terminal protein kinase (JNK) resulted in the
inactivation of the complex (26). It was also found
that fenofibrate inhibited JNK activation (27).
Therefore, an increase in 2-OGDH activity upon
fibrates treatment could be associated with
decreased phosphorylation of the complex.
It also seems likely that fibrates increased 2-
OGDH activity by attenuating renal oxidative stress.
2-OGDH complex is uniquely sensitive to oxidative
stress, capable of undergoing free radical-mediated
inhibition (28, 29). Fibrates reduce NAD(P)H oxi-
dase activity and increase the activities of free radi-
cal scavenging enzymes, including superoxide dis-
mutase, catalase, and glutathione peroxidase (30,
31).
It was found that low doses of bezafibrate and
fenofibrate did not change renal mRNA levels for
PPARα. This result is in good agreement with our
recent study on the effect of fibrates on liver PPARα
(10). In addition, it is consistent with results
obtained by Nakajima et al. (32) who showed that
administration of low, clinically relevant doses of
fibrates resulted in a reduction of serum/liver TG but
was not associated with changes in mRNA level for
PPARα.
It is probable that an increase in 2-OGDH
activity induced by fibrates may lead to changes in
renal metabolism. It has been demonstrated that
stimulation of 2-OGDH triggers a significant
decrease in 2-OG concentration (33). 2-OG is a mas-
Figure 3. Effect of increasing doses of fenofibrate on renal 2-OGDH catalytic subunits E1 (a) and E2 (b) mRNA levels. Rats were fed a
low-protein diet and administered with 5, 10 or 20 mg/kg b.wt/day of fenofibrate or given only the vehicle (control group ñ 0 g/kg b.wt/day
fenofibrate). The relative levels of E1 and E2 mRNA were measured by means of semi-quantitative RT-PCR, quantitated by densitometry
then normalized to β-actin mRNA (in the same sample) and expressed relative to the control rats (arbitrary units-% of control). Right panel:
representative agarose gel. Left panel: bar graph displaying the mean values ± SD.
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Figure 5. Effect of increasing doses of fenofibrate (a) and bezafibrate (b) on mRNA levels for PPARα. Rats were fed a low-protein diet
and administered with 5, 10 or 20 mg/kg b.wt/day of fibrate or given only the vehicle (control group ñ 0 g/kg b.wt/day fibrate). The rela-
tive levels mRNA levels for PPARα were measured by means of semi-quantitative RT-PCR, quantitated by densitometry then normalized
to β-actin mRNA (in the same sample) and expressed relative to the control rats (arbitrary units-% of control). Right panel: representative
agarose gel. Left panel: bar graph displaying the mean values ± SD.
Figure 4. Effect of increasing doses of bezafibrate on renal 2-OGDH catalytic subunits E1 (a) and E2 (b) mRNA levels. Rats were fed a
low-protein diet and administered with 5, 10 or 20 mg/kg b.wt/day of bezafibrate or given only the vehicle (control group ñ 0 g/kg b.wt/day
bezafibrate). The relative levels of E1 and E2 mRNA were measured by means of semi-quantitative RT-PCR, quantitated by densitome-
try then normalized to β-actin mRNA (in the same sample) and expressed relative to the control rats (arbitrary units-% of control). Right
panel: representative agarose gel. Left panel: bar graph displaying the mean values ± SD.
PPAR
PPAR
Low doses of fenofibrate and bezafibrate stimulate renal 2-oxoglutarate... 287
ter regulator of multiple metabolic and cellular path-
ways in different tissues, including kidneys.
Schoolwerth et al. (33) found that an increase in 2-
OGDH flux and reduced 2-OG level were associat-
ed with enhanced renal ammoniagenesis. In addi-
tion, a decline in 2-OG was connected with an accel-
eration of renal gluconeogenesis (34). Furthermore,
2-OG regulates renal Cl-dependent HCO3- secretion
and electroneutral transepithelial NaCl reabsorption
(35). Therefore, it may be reasonable to assume that
the stimulation of 2-OGDH by fibrates could modi-
fy crucial metabolic pathways in kidneys.
Since 2-OGDH catalyzes the conversion of 2-
OG to succinyl-CoA in the presence of the CoA
thereby reducing NAD+ to NADH, the increase in 2-
OGDH activity would be expected to decrease NAD+
in mitochondria. NAD+ serves as a key cofactor for
numerous enzymes involved in energy metabolism
and also has several other important cellular func-
tions, including regulation of multiple cell signaling
pathways (36, 37). It was demonstrated that the
decline in renal level of NAD+ was associated with a
general reduction in mitochondrial function (38). In
addition, NAD+ depletion is emerging as a major
contributor to the pathogenesis of renal diseases (39).
Some reports have indicated that fibrates can
induce renal impairment (13, 15, 40). Fibrate thera-
py is associated with elevation in serum creatinine
and reduced estimated glomerular filtration rates
(14, 41). The mechanism of this effect has not been
fully elucidated. Ncube et al. (42) suggested that the
decrease in estimated glomerular filtration rate upon
fibrates treatment was a genuine effect on kidney
functions rather than a change in creatinine metabo-
lism. Kidney functions were not evaluated in the
present study. However, taking into account
obtained results one cannot exclude the possibility
that in condition of protein restriction fibrates dis-
turb renal metabolism leading to alternation in kid-
ney functions. 
In conclusion, obtained results indicate that
low doses of fenofibrate and bezafibrate up-regulat-
ed renal 2-OGDH activity in rats fed a low-protein
diet. Stimulation of 2-OGDH was not accompanied
by changes in mRNA levels for catalytic subunits,
E1 and E2 suggesting that fibrates exert some
effects on factors regulating the complex activity. In
addition, the effect of fibrates was not associated
with changes in the mRNA level for PPARα. It is
conceivable that fibrate-induced stimulation of 2-
OGDH activity can affect renal metabolism and
contribute to changes in kidney functions. Further
studies are required to elucidate the influence of
fibrates on kidneys. 
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